ReviewCNS drugs2023
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data.
Review in CNS drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review.Psychological medicine · 2025Pooled it
- Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis.Epidemiology and psychiatric sciences · 2025Pooled it
- Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review.Molecular psychiatry · 2025Pooled it
- Antidepressants for low back pain and spine-related leg pain.The Cochrane database of systematic reviews · 2025Pooled it
- Pooled it
- Trial
- Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Psychopharmacological Mechanisms of Antidepressant Withdrawal: Insights From Venlafaxine.Human psychopharmacology · 2026Review
- Reported Safety Practices of Publicly Advertised Psychedelic Retreats.JAMA network open · 2026Article
- Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel.Therapeutic advances in psychopharmacology · 2026Article
- Increasing Prevalence of Long-Term Antidepressant Use in Australia: A Retrospective Observational Study.Pharmacoepidemiology and drug safety · 2025Observational
- False reassurances based on inadequate data not helpful.Psychological medicine · 2025Article
- Healthcare Providers' Perspectives on Antidepressant Discontinuation: A Focus Group Study.Basic & clinical pharmacology & toxicology · 2025Article
- Hidden Costs: The Clinical and Research Pitfalls of Mistaking Antidepressant Withdrawal for Relapse.Psychotherapy and psychosomatics · 2025Article
- The role of empathy in antidepressant withdrawal.Therapeutic advances in psychopharmacology · 2025Article
- Potential deprescribing indications for antidepressants between 2012 and 2019: repeated cross-sectional analysis in two Scottish health boards.BMC medicine · 2024Article
- Acceptability and optimisation of resources to support antidepressant cessation: a qualitative think-aloud study with patients in Australian primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024Article
- The lived experience of withdrawal from Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants: A qualitative interview study.Health expectations : an international journal of public participation in health care and health policy · 2024Article
- Mechanisms of SSRI Therapy and Discontinuation.Current topics in behavioral neurosciences · 2024Review
- Efficacy of bifidobacterium-related preparations on depression: the first meta-analysis.Frontiers in psychiatry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adaptation of the brain to the presence of a drug predicts withdrawal on cessation. The outcome of adaptation is often referred to as 'physical dependence' in pharmacology, as distinct from addiction, although these terms have unfortunately become conflated in some diagnostic guides. Physical dependence to antidepressants may occur in some patients, consistent with the fact that some patients experience withdrawal effects from these medications. It is thought that longer duration of use, higher dose and specific antidepressants affect the risk of antidepressant withdrawal effects as they might cause greater adaptation of the brain. We searched PubMed for relevant systematic reviews and other relevant analyses to summarise existing data on determinants of antidepressant withdrawal incidence, severity and duration. Overall, data were limited. From survey data, increased duration of use was associated with an increased incidence and severity of withdrawal effects, consistent with some evidence from data provided by drug manufacturers. Duration of use may be related to duration of withdrawal effects but data are heterogenous and sparse. Serotonin and noradrenaline reuptake inhibitors and paroxetine are associated with higher risks than other antidepressants, though data for some antidepressants are lacking. Higher doses of antidepressant has some weak association with an increased risk of withdrawal, with some ceiling effects, perhaps reflecting receptor occupancy relationships. Past experience of withdrawal effects is known to predict future risk. Based on these data, we outline a preliminary rubric for determining the risk of withdrawal symptoms for a particular patient, which may have relevance for determining tapering rates. Given the limited scope of the current research, future research should aim to clarify prediction of antidepressant withdrawal risk, especially by examining the risk of withdrawal in long-term users of medication, as well as the severity and duration of effects, to improve the preliminary tool for predictive purposes. Further research into the precise adaptations in long-term antidepressant use may improve the ability to predict withdrawal effects for a particular patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.